Lung Cancer News

Friends of Cancer Research appointed Edward S. Kim, MD, MBA, FACP, FASCO, to its board of directors.

A study of more than 20,000 patients with non-small cell lung cancer in Korea showed improvements in survival outcomes across all stages of disease between 2010 and 2020 amid increased use of molecular testing and targeted treatments.

Doctoral researchers from 11 European institutions and four companies have formed a research network dedicated to developing molecules that stimulate the immune response to tumor cells.

The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for advanced malignant pleural mesothelioma, according to the agent’s manufacturer.

An artificial intelligence algorithm that uses computational analysis to identify possible therapeutic targets for glioblastoma multiforme and other types of cancer could have broad treatment implications, according to its developers.

Osimertinib conferred a statistically significant and clinically meaningful improvement in OS compared with placebo among patients with early-stage EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.

Traditional histology typically guides treatment decisions for patients with colorectal cancer and various other malignancies, but it is unable to reveal a tumor’s molecular or structural features.

Today marks International Women’s Day.

An expansion of lung cancer screening criteria to include those who are younger and with less smoking exposure would increase eligibility for women and Black individuals who could benefit, results of a retrospective study showed.